In this study, thePNA sequences PNA1, PNA2, and PNA3 were selected for their potentialas anti-miR therapeutics in the context of cystic fibrosis, an autosomalrecessive genetic disease deriving from misfunctioning of cystic fibrosistransmembrane conductance regulator (CFTR) protein. Here, CFTR is linked to cystic fibrosis.